

March 13, 2023

TRANSFUSION MEDICINE

Provision of Solvent Detergent Plasma

Date effective: March 27, 2023

Background Information:

Octaplasma is blood group specific, pathogen-inactivated human plasma for transfusion. The product is manufactured from US source plasma by Octapharma using solvent/detergent (S/D) pathogen-inactivation method. The resulting product is an alternative to frozen plasma (untreated) components manufactured by Canadian Blood Services (e.g., apheresis frozen plasma [AFP], frozen plasma [FP]) but with reduced risk of transmitting infection from enveloped viruses.

The volume of each unit of Octaplasma is 200 mL—lower than the volumes of frozen plasma (untreated) units (approximately 289mL for FP, and 249mL for AFP). Each unit of Octaplasma has consistent and standardized clotting factor content compared with single-donor plasma for which donor-to-donor variation exists. In Octaplasma, all clotting factors are present at a minimum concentration of 0.5 IU/mL with the exception of plasmin inhibitor which is at a reduced concentration.

Change in Test Procedure:

Octaplasma use has been available in Manitoba but previously restricted to patients requiring high volume or chronic transfusions and who experienced a clinically significant allergic reaction to plasma or had an existing lung disorder making them more susceptible to the effects of a TRALI reaction. Restricted access to Octaplasma will be lifted as of March 2023 and almost full conversion to pathogen-reduced plasma (at least 80% Octaplasma, though hospitals may opt for a higher percentage up to 100%) will be expected by September 2023.

Frozen plasma (untreated) will remain available as hospitals use up their current inventory and CBS will retain a small inventory.

References/Resources:

- CBS Customer Letter # [2023-04](#)
- Slide deck for [Clinical](#)

Patient Impact:

- Lower rates of allergic reactions and lower risk of transfusion transmitted infections.

System Improvements:

- Decreased systemic costs from managing adverse events from plasma transfusion.

More Information:

www.octaplasma.ca

[FAQ: Solvent detergent \(S/D\) treated plasma \(Octaplasma\) | Professional Education \(blood.ca\)](#)

Contact Information:

Charles Musuka, Medical Director, Transfusion Medicine, Shared Health, 204 237 2471,
cmusuka@sharedhealthmb.ca